Here’s what you should know:
1. Dr. Plotkin has almost 30 years experience in pharmaceuticals, including all phases of drug development.
2. She comes to Ritter from ActivX Biosciences, where she was senior director of worldwide clinical development.
3. At Ritter, Dr. Plotkin will oversee the development of the company’s lactose intolerance drug, RP-G28. Ritter is launching a phase 3 clinical trial of approximately 500 patients this summer.
4. Company Co-Founder and President Andrew Ritter said, “Dr. Plotkin has extensive experience and knowledge of clinical trials and the FDA approval process. Following our end-of-phase 2 meeting, we have a clear path forward into our phase 3 program from the FDA. We look forward to having Dr. Plotkin actively lead our clinical team as we are committed to ensuring that the clinical development of RP-G28 is executed safely with scientific rigor and high-quality pharmaceutical execution.”
More articles on leadership:
Study: Outpatient shoulder surgery in ASCs safe for patients 65+ years
How leading antimicrobial stewardship programs combat antibiotic resistance — 3 key takeaways
Cookeville Center for Pain Management owner to pay $1.45M for prescribing “useless” painkillers
